Regulation of type 1 plasminogen activator inhibitor gene expression in cultured bovine aortic endothelial cells. Induction by transforming growth factor-beta, lipopolysaccharide, and tumor necrosis factor-alpha
- PMID: 2499579
Regulation of type 1 plasminogen activator inhibitor gene expression in cultured bovine aortic endothelial cells. Induction by transforming growth factor-beta, lipopolysaccharide, and tumor necrosis factor-alpha
Abstract
Cultured bovine aortic endothelial cells (BAEs) synthesize and secrete type 1 plasminogen activator inhibitor (PAI-1), an Mr 50,000 glycoprotein which inhibits both urokinase and tissue-type plasminogen activators. The synthesis of PAI-1 in BAEs is positively regulated by a variety of agents. To elucidate the mechanisms which govern expression of the PAI-1 gene, total cytoplasmic RNA was prepared from BAEs and analyzed by Northern blotting using a 1.3-kilobase (kb) human PAI-1 cDNA probe. Hybridization under conditions of high stringency revealed two bovine PAI-1 RNA species, 3.0 and 1.6 kb in length. The ratio of the two species was approximately 4:1. The 3.0-kb mRNA was bound by oligo(dT)-cellulose, whereas the 1.6-kb form was not, suggesting that the latter form lacked a poly(A) terminus. Treatment of BAEs with transforming growth factor beta (TGF-beta), bacterial lipopolysaccharide (LPS), or tumor necrosis factor alpha (TNF-alpha) markedly enhanced the steady-state levels of both RNA species. In each case, increases were detectable within 1 h, and maximal effects (i.e. greater than 30-fold increase) were observed between 6 and 18 h of treatment, followed by a decline to near-basal levels by 48 h. The response to each of these agents was dose-dependent, with maximal induction observed at concentrations of 10 ng/ml TGF-beta, 10 ng/ml LPS, and 25 ng/ml TNF-alpha. Induction of PAI-1 mRNA by these agents was not blocked by the protein synthesis inhibitor cycloheximide, suggesting that de novo protein synthesis was not required. In fact, treatment with cycloheximide (2 micrograms/ml) alone also increased PAI-1 mRNA levels. Treatment with cycloheximide in combination with TGF-beta, LPS, or TNF-alpha further enhanced the accumulation of PAI-1 mRNA. Nuclear transcription run-on experiments indicated that these agents elevated the rate of PAI-1 gene transcription 20-30-fold and that gene template activity was temporally correlated with the accumulation of PAI-1 mRNA. These data are consistent with the conclusion that the observed increases in PAI-1 steady-state mRNA levels result from primary effects of these agents on the rate of PAI-1 gene transcription.
Similar articles
-
Regulation of plasminogen activator inhibitor-1 mRNA in human endothelial cells.Thromb Haemost. 1988 Aug 30;60(1):63-7. Thromb Haemost. 1988. PMID: 2460966
-
Regulation of mRNAs for type-1 plasminogen activator inhibitor, fibronectin, and type I procollagen by transforming growth factor-beta. Divergent responses in lung fibroblasts and carcinoma cells.J Biol Chem. 1988 Mar 5;263(7):3111-5. J Biol Chem. 1988. PMID: 3125175
-
Regulation of the expression of type 1 plasminogen activator inhibitor in Hep G2 cells by epidermal growth factor.J Biol Chem. 1988 Nov 5;263(31):15845-8. J Biol Chem. 1988. PMID: 2846525
-
Fibrinolytic system of vascular endothelial cells. Role of plasminogen activator inhibitors.Haemostasis. 1988;18(4-6):328-41. doi: 10.1159/000215815. Haemostasis. 1988. PMID: 3148526 Review.
-
Oxidative stress, plasminogen activator inhibitor 1, and lung fibrosis.Antioxid Redox Signal. 2008 Feb;10(2):303-19. doi: 10.1089/ars.2007.1903. Antioxid Redox Signal. 2008. PMID: 17979497 Free PMC article. Review.
Cited by
-
Urokinase-receptor biosynthesis, mRNA level and gene transcription are increased by transforming growth factor beta 1 in human A549 lung carcinoma cells.EMBO J. 1991 Nov;10(11):3399-407. doi: 10.1002/j.1460-2075.1991.tb04904.x. EMBO J. 1991. PMID: 1655420 Free PMC article.
-
Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-alpha, and transforming growth factor-beta.J Clin Invest. 1991 Oct;88(4):1346-53. doi: 10.1172/JCI115440. J Clin Invest. 1991. PMID: 1918385 Free PMC article.
-
Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice.J Clin Invest. 1994 Sep;94(3):1320-7. doi: 10.1172/JCI117451. J Clin Invest. 1994. PMID: 7521887 Free PMC article.
-
Opposite and independent actions of cyclic AMP and transforming growth factor beta in the regulation of type 1 plasminogen activator inhibitor expression.Biochem J. 1992 Nov 1;287 ( Pt 3)(Pt 3):855-62. doi: 10.1042/bj2870855. Biochem J. 1992. PMID: 1332686 Free PMC article.
-
Tissue factor mRNA in THP-1 monocytic cells is regulated at both transcriptional and posttranscriptional levels in response to lipopolysaccharide.Mol Cell Biol. 1991 Sep;11(9):4732-8. doi: 10.1128/mcb.11.9.4732-4738.1991. Mol Cell Biol. 1991. PMID: 1875949 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous